イソクエン酸脱水酵素阻害剤のパイプライン・インサイト2018

【英語タイトル】Isocitrate Dehydrogenase (IDH1) inhibitors -Pipeline Insights, 2018

DelveInsightが出版した調査資料(DIMR2016727)・商品コード:DIMR2016727
・発行会社(調査会社):DelveInsight
・発行日:2018年12月
・ページ数:n/a
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、世界におけるイソクエン酸脱水酵素阻害剤のパイプライン動向について調査・分析し、以下の構成でお届けいたします。

・イソクエン酸脱水酵素阻害剤の概要
・イソクエン酸脱水酵素阻害剤のパイプライン概要
・企業別開発中のイソクエン酸脱水酵素阻害剤
・後期治験段階の薬剤(Filed & Phase III):比較分析
・中期治験段階の薬剤(Phase II):比較分析
・初期治験段階の薬剤(Phase I & IND Filed):比較分析
・薬剤候補のプロファイル
・イソクエン酸脱水酵素阻害剤の評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価
・開発が中止された薬剤リスト
・開発休止中の薬剤リスト
・イソクエン酸脱水酵素阻害剤開発に取り組んでいる企業リスト
・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “Isocitrate Dehydrogenase (IDH1) inhibitors-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Isocitrate Dehydrogenase (IDH1) inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Isocitrate Dehydrogenase (IDH1) inhibitors. DelveInsight’s Report also assesses the Isocitrate Dehydrogenase (IDH1) inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitive pipeline landscape of Isocitrate Dehydrogenase (IDH1) inhibitors
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Isocitrate Dehydrogenase (IDH1) inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Isocitrate Dehydrogenase (IDH1) inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Isocitrate Dehydrogenase (IDH1) inhibitors Overview
• Isocitrate Dehydrogenase (IDH1) inhibitors Disease Associated
• Isocitrate Dehydrogenase (IDH1) inhibitors Pipeline Therapeutics
• Isocitrate Dehydrogenase (IDH1) inhibitors Therapeutics under Development by Companies
• Isocitrate Dehydrogenase (IDH1) inhibitors Filed and Phase III Products
• Comparative Analysis
• Isocitrate Dehydrogenase (IDH1) inhibitors Phase II Products
• Comparative Analysis
• Isocitrate Dehydrogenase (IDH1) inhibitors Phase I and IND Filed Products
• Comparative Analysis
• Isocitrate Dehydrogenase (IDH1) inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Isocitrate Dehydrogenase (IDH1) inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Isocitrate Dehydrogenase (IDH1) inhibitors – Discontinued Products
• Isocitrate Dehydrogenase (IDH1) inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for Isocitrate Dehydrogenase (IDH1) inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Isocitrate Dehydrogenase (IDH1) inhibitors by Therapy Area, 2018
• Number of Products under Development for Isocitrate Dehydrogenase (IDH1) inhibitors, 2018
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2018
• Comparative Analysis Phase II Products, 2018
• Comparative Analysis Phase I and IND Filed Products, 2018
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2018
• Drug Candidates Profiles
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Monotherapy Products
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Combination Products
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Route of Administration
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Stage and Route of Administration
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Molecule Type
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Stage and Molecule Type
• Isocitrate Dehydrogenase (IDH1) inhibitors Therapeutics – Discontinued Products
• Isocitrate Dehydrogenase (IDH1) inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2018


List of Figures
• Number of Products under Development for Isocitrate Dehydrogenase (IDH1) inhibitors by Therapy Area, 2018
• Number of Products under Development for Isocitrate Dehydrogenase (IDH1) inhibitors, 2018
• Filed and Phase III Products, 2018
• Phase II Products, 2018
• Phase I and IND Filed Products, 2018
• Discovery and Pre-Clinical Stage Products, 2018
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Monotherapy Products
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Combination Products
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Route of Administration
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Stage and Route of Administration
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Molecule Type
• Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Stage and Molecule Type


【レポートのキーワード】

イソクエン酸脱水酵素阻害剤、医薬品、製薬、研究開発、パイプライン、治療、治験

★調査レポート[イソクエン酸脱水酵素阻害剤のパイプライン・インサイト2018] (コード:DIMR2016727)販売に関する免責事項を必ずご確認ください。
★調査レポート[イソクエン酸脱水酵素阻害剤のパイプライン・インサイト2018]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆